Drug-eluting Stents Market: Decoding the Newest Generation of Drug-eluting Stents, and Beyond

As the healthcare industry reforms to convert the current fee-for-service model to fee-for-value model, intense focus has been placed on the reduction in patient complications, and number and length of hospital stay. Interventional cardiology, in particular, is at a pivot point with remarkable evolution taking place in device technology, operator techniques, and clinical safety and efficacy. Enormous advances have been made in the treatment of coronary artery disease, and the era of 'stent implantation' is upon today’s patients. Moreover, the advent of drug-eluting stents (DES) has considerably changed and revolutionized the interventional landscape, and made angioplasty more predictable, as such, catalyzing the growth of the drug-eluting stents market.

In recent years, acceleration in device development, advances in adjunctive pharmacology, and improved information systems have turned the spotlight on the drug-eluting stents market. According to the latest research by Transparency Market Research (TMR)on the drug eluting stents market, the worldwide sales of drug-eluting stents will reach ~US$ 5.5 billion in 2019, recording a promising CAGR of ~5% during the period of 2019-2027.

drug eluting stents market infographic

Get a glimpse of the in-depth analysis through our Report Brochure

Drug-eluting Stents Market: Bioresorbable Stents – The Product of Choice

Rapid advancements in stent designs and delivery systems have made stenting much easier to integrate in interventional milieu – reducing the cases of restenosis, even for the most complex lesions. However, with the occurrence of stent thrombosis, manufacturers in the drug-eluting stents market are focusing on the development of newer generation of drug-eluting stents that facilitate the eradication of this fatal outcome. Bioresorbable stent (BRS) technology has been gaining increasing momentum in the most recent generation of drug-eluting stents, which are associated with significant reduction in the risk of early and late thrombosis.

While DES based on durable polymers continue to account for relatively high sales, manufacturers operating in the drug-eluting stents market are focusing on innovating and increasing the production of biodegradable polymer-based DES, as such polymers degrade efficiently after the elution of drugs. In addition, rising safety concerns regarding the usage of third-generation drug-eluting stents have prompted the development of fully-biodegradable or bioresorbable stents due to their potential advantages in decreasing inflammatory response, improving drug elution kinetics, and predictably inhibiting restenosis and late stent thrombosis.

Bioresorbable drug-eluting stents/scaffolds are likely to represent a crucial step in stent technology development, and provide the added benefit of completely degrading, allowing the recovery of vessel vasoreactivity and endothelial function. TMR’s analysts forecast that, the fourth-generation of drug-eluting stents will record an impressive CAGR of ~52% during the predefined timeframe.

To know the scope of our report Get a Sample on Drug-eluting Stents Market

Will Developing Nations Offer Greater Growth Opportunities to the Global DES Market?

While stringent regulatory requirements set by the FDA have long affected the commercialization of various drug-eluting stents in the United States, increased access to advanced technologies and successful outcomes in clinical trials have been recently influencing the FDA approvals of newer generation of products. For instance, in 2019, BIOTRONIK announced the FDA approval of its ultrathin Orsiro drug-eluting stent (DES) system, while the same device received its CE marking in 2011. Such factors, along with robust R&D on cardiovascular interventions and increase in demand for bioresorbable drug-eluting stents, are likely to play an important role in the strategic expansion of manufacturers in developed drug-eluting stents markets.

Leading stakeholders in the drug-eluting stents market continue to view developing countries in Asia Pacific from a target market perspective, on the account of increased healthcare expenditure per capita and favorable government initiatives to improve the industry’s infrastructure. However, the emergence of a large number of local players along with government reforms is playing a major role in deciding the prices of stents, which has represented a potential threat to the steady expansion of key players. For instance, price caps initiated by the National Pharmaceutical Pricing Authority (NPPA) in India has led to the withdrawal of DES systems by global manufacturers, while creating a golden opportunity for local players.

drug eluting stents market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report 

Analysts’ Viewpoint of the Drug-eluting Stents Market

Although significant advances have been made, the most reliable drug-eluting stent systems are yet to be developed, according to TMR’s analysts. Considering the risk of late thrombosis among patients, manufacturers will need to conduct larger trials and longer follow-ups to assess the effectiveness of their novel devices. According to TMR’s analysts, the success of key drug-eluting stents market players in developing countries with high pricing pressure will hinge on offering high-quality products at affordable prices. Local players, on the other hand, will need to focus on developing the latest generation of drug-eluting stents to retain and attract new segments of end users.

  • According to Transparency Market Research’s latest market report on the drug-eluting stents for the historical period of 2017 & 2018 and forecast from 2019 to 2027, the introduction of fully-bioresorbable stents, rise in the prevalence of cardiovascular diseases, and product launches by key market players are key factors that are anticipated to drive the market.
  • Globally, in terms of revenue, the drug-eluting stents market is estimated to reach ~US$ 8.3 Bn in 2027. The market is expected to expand at a CAGR of ~5%, in terms of value, during the forecast period.

Introduction of Fully-bioresorbable Stents: A Key Driver

  • The evolution of drug-eluting stent technologies has led to a revolution in the treatment of cardiovascular diseases, and has opened new pathways to percutaneous coronary interventions.
  • The development of fully-bioresorbable stents or scaffolds was initiated with an objective to avoid restenosis, ensure safety, and improve the lives of patients.
  • Several market players have recently launched fully-bioresorbable stents or scaffolds with no stent residue left after drug elution. This enables quicker healing of the heart vessels and ensures minimal damage to the tissues.
  • In April 2017, Reva Medical received the CE mark for the Fantom drug-eluting bioresorbable coronary scaffold, enabling the company to gain access to the drug-eluting stents market in Europe.

Increase in Prevalence of Cardiovascular Diseases Drives the Drug-eluting Stents Market

  • The burden of cardiovascular diseases (CVDs) is on the rise globally, owing to numerous risk factors such as smoking, diabetes, obesity, and lifestyle changes.
  • According to the World Health Organization (WHO), in 2016, 17.9 million people died due to CVDs, accounting for 31% of deaths, worldwide.
  • As per the American Heart Association, in the U.S., there were 840,678 deaths due CVD in 2016. Furthermore, between 2013 and 2016, 121.5 million adults in the U.S. were diagnosed with some form of CVD. In the U.S., in 2016, coronary diseases was the leading cause of deaths, and accounted for 43.2% of overall deaths.
  • The burden of CVD is higher in countries across Asia Pacific. According to Lancet, deaths due to coronary diseases are increasing in the rural areas in India, and are expected to be higher than those in urban areas in the country.
  • As such, increase in the prevalence of CVD is anticipated to drive the drug-eluting stents market.

Global Drug-eluting Stents Market: Key Segments

  • In this market report, TMR proposes that, in terms of product, the polymer-based segment dominated the global drug-eluting stents market in 2018. The segment is expected to maintain its dominance during the forecast period. Expansion of the segment is attributed to the availability of a wide range of polymer-based drug-eluting stents in the market, and their high rate of adoption for coronary interventions across the globe. Furthermore, recent product approvals are likely to boost the segment during the forecast period. In February 2018, Medtronic launched Resolute Onyx 2.0 mm DES in the U.S. This product enabled cardiologists to treat patients with coronary artery disease, and have small vessels that cannot be treated with larger size stent technologies available in the drug-eluting stents market.
  • In terms of drug, the sirolimus segment is estimated to expand at a high CAGR during the forecast period. Sirolimus is an extensively used drug for stents. Sirolimus coated drug-eluting stents have less late lumen loss and less angiographic restenosis.
  • In terms of generation, the global drug-eluting stents market has been classified into 1st generation, 2nd generation, 3rd generation, and 4th generation. The 3rd generation drug eluting stents segment is anticipated to hold a notable share of the global drug-eluting stents market by 2027. The 4th generation DES segment is projected to expand at a high CAGR during the forecast period.
  • Based on scaffold, the cobalt-chromium segment is anticipated to dominate the global drug-eluting stents market from 2019 to 2027, which is attributed to an increase in the use of cobalt-chromium stents and several market players manufacturing cobalt-chromium-based stents. Flexibility, long shelf-life, and better biocompatibility of cobalt-chromium-based drug-eluting stents are anticipated to attribute to its leading share of the global market.
  • Based on application, the global drug-eluting stents market has been bifurcated into coronary diseases and peripheral vascular diseases. The peripheral vascular diseases segment is likely to gain significant share and offer lucrative opportunities during the forecast period. This is attributed to an increase in the demand for drug-eluting vascular stents for the treatment of peripheral vascular diseases. As per the Cochrane Database Syst Rev 2016, in Western countries, the prevalence of peripheral vascular diseases is increasing among people above 50 years of age.
  • In terms of end user, the global drug-eluting stents market has been bifurcated into hospitals and ambulatory surgical centers. The ambulatory surgical centers segment is projected to expand at a notable CAGR due to a shift of coronary interventions from hospitals to ambulatory surgical centers.
  • The drug-eluting stents market size and forecast for each of these segments has been provided for the duration of 2017 to 2027. The CAGR of respective segments has also provided for the forecast period from 2019 to 2027, with 2018 as the base year.

Drug-eluting stents Market: Competition Landscape

  • Prominent players operating in the global drug-eluting stents market are profiled based on key aspects such as company overview, product portfolio, financial overview, recent developments, and competitive business strategies.

Major companies profiled in the drug-eluting stents market report include

  • Biotronik
  • Boston Scientific Corporation
  • Medtronic
  • Abbott
  • Biosensors International Group, Ltd ( Bluesail Medical Co., Ltd.)
  • MicroPort Scientific Corporation
  • Terumo Corporation
  • Cook
  • ​STENTYS SA, and Medinol Ltd.

Adoption of Expansion Strategies by Major Players in Drug-eluting Stents Market

  • Innovation in drug-eluting stents, increase in number of clinical trials, and geographic expansion were key strategies adopted by major players operating in the global drug-eluting stents market.
  • In February 2019, Medtronic received FDA approval for Resolute DES platforms such as the Resolute Onyx and Resolute Integrity DES, for expanded indications such as de novo chronic total occlusion (CTO).
  • In August 2018, Firehawk received regulatory approval from Malaysia's Medical Device Authority, enabling the company to gain access to the drug-eluting stents market in Malaysia.
  • In the global drug-eluting stents market report, we have discussed individual strategies, followed by company profiles of the manufacturers of drug-eluting stents. The ‘Competitive Landscape’ section is included in the drug-eluting stents market report to provide readers with a dashboard view and a company market share analysis of the key players operating in the global drug-eluting stents market.

Drug-eluting Stents Market – Segmentation

The report provides an all-inclusive segmental analysis of the global drug-eluting stents market, which has been classified into seven broader categories – product, drug, generation, scaffold, application, end user, and region. Analysis of key geographies that account for growth opportunities or hold substantial share has also been included as part of the geographic analysis of the drug-eluting stents market.

Product

Polymer-based

  • Biodegradable Polymers
  • Durable Polymers

Polymer-free

Drug

Sirolimus

Paclitaxel

Zotarolimus

Everolimus

Biolimus

Others

Generation

1st Generation

2nd Generation

3rd Generation

4th Generation

Scaffold

Cobalt-Chromium

Platinum-Chromium

Nitinol

Biodegradable

Others

Application

Coronary Diseases

Peripheral Vascular Diseases

End User

Hospitals

Ambulatory Surgical Centers

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Frequently Asked Questions

Drug-eluting stents market is estimated to reach ~US$ 8.3 Bn in 2027

Drug-eluting stents market is expected to expand at a CAGR of ~5% during 2019 - 2027

Drug-eluting stents market is driven by increase in numbers of geriatric people, increase in research and development (R&D) activities and technological advancement

North America to be a Prominent Region in the global drug-eluting stents market over the forecast period

Key players in the drug-eluting stents market include Boston Scientific Corporation, Medtronic, Abbott, Biosensors International Group, Ltd ( Bluesail Medical Co., Ltd.), Biotronik, MicroPort Scientific Corporation

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Drug-eluting Stents Market

    3.1. Market Overview
    3.2. Introduction
    3.3. Product Definition
    3.4. Industry Evolution / Developments
4. Overview
    4.1. Market Dynamics
        4.1.1. Drivers
        4.1.2. Restraints
        4.1.3. Opportunities
    4.2. Global Drug-eluting Stents Market Analysis and Forecast, 2017–2027
5. Key Insights
    5.1. Breakthrough Technologies in Drug-eluting Stents Market
    5.2. Regulatory Approvals in Drug-eluting Stents Market
    5.3. Strategic Approaches by Market Players (Acquisitions, Partnerships, and Distribution Agreements, etc.)
    5.4. Product Launch
6. Global Drug-eluting Stents Market Analysis and Forecast, by Product 
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Global Drug-eluting Stents Market Value Forecast, by Product, 2017–2027
        6.3.1. Polymer-based
            6.3.1.1. Biodegradable Polymers
            6.3.1.2. Durable Polymers
        6.3.2. Polymer-free
    6.4. Global Drug-eluting Stents Market Attractiveness, by Product 
7. Global Drug-eluting Stents Market Analysis and Forecast, by Drug 
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Global Drug-eluting Stents Market Value Forecast, by Drug, 2017–2027
        7.3.1. Sirolimus
        7.3.2. Paclitaxel
        7.3.3. Zotarolimus
        7.3.4. Everolimus 
        7.3.5. Biolimus
        7.3.6. Others
    7.4. Global Drug-eluting Stents Market Attractiveness, by Drug 
8. Global Drug-eluting Stents Market Analysis and Forecast, by Generation 
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Global Drug-eluting Stents Market Value Forecast, by Generation, 2017–2027
        8.3.1. 1st Generation
        8.3.2. 2nd Generation
        8.3.3. 3rd Generation
        8.3.4. 4th Generation
    8.4. Market Attractiveness, by Generation 
9. Global Drug-eluting Stents Market Analysis and Forecast, by Scaffold Type 
    9.1. Introduction & Definition
    9.2. Key Findings / Developments
    9.3. Global Drug-eluting Stents Market Value Forecast, by Scaffold Type, 2017–2027
        9.3.1. Cobalt Chromium
        9.3.2. Platinum Chromium
        9.3.3. Nitinol
        9.3.4. Biodegradable
        9.3.5. Others
    9.4. Global Drug-eluting Stents Market Attractiveness, by Scaffold Type 
10. Global Drug-eluting Stents Market Analysis and Forecast, by Application 
    10.1. Introduction & Definition
    10.2. Key Findings / Developments
    10.3. Global Drug-eluting Stents Market Value Forecast, by Application, 2017–2027
        10.3.1. Coronary Diseases
        10.3.2. Peripheral Vascular Diseases
    10.4. Global Drug-eluting Stents Market Attractiveness, by Application 
11. Global Drug-eluting Stents Market Analysis and Forecast, by End-user 
    11.1. Introduction & Definition
    11.2. Key Findings / Developments
    11.3. Global Drug-eluting Stents Market Value Forecast, by End-user, 2017–2027
        11.3.1. Hospitals
        11.3.2. Ambulatory Surgical Centers
    11.4. Global Drug-eluting Stents Market Attractiveness, by End-user 
12. Global Drug-eluting Stents Market Analysis and Forecast, by Region
    12.1. Key Findings
    12.2. Global Drug-eluting Stents Market Value Forecast, by Region
        12.2.1. North America 
        12.2.2. Europe 
        12.2.3. Asia Pacific 
        12.2.4. Latin America 
        12.2.5. Middle East & Africa 
    12.3. Global Drug-eluting Stents Market Attractiveness, by Country/Region
13. North America Drug-eluting Stents Market Analysis and Forecast
    13.1. Introduction
    13.2. Key Findings
    13.3. North America Drug-eluting Stents Market Value Forecast, by Product, 2017–2027
        13.3.1. Polymer-based
            13.3.1.1. Biodegradable Polymers
            13.3.1.2. Durable Polymers
        13.3.2. Polymer-free
    13.4. North America Drug-eluting Stents Market Value Forecast, by Drug, 2017–2027
        13.4.1. Sirolimus
        13.4.2. Paclitaxel
        13.4.3. Zotarolimus
        13.4.4. Everolimus 
        13.4.5. Biolimus
        13.4.6. Others
    13.5. North America Drug-eluting Stents Market Value Forecast, by Generation, 2017–2027
        13.5.1. 1st Generation
        13.5.2. 2nd Generation
        13.5.3. 3rd Generation
        13.5.4. 4th Generation
    13.6. North America Drug-eluting Stents Market Value Forecast, by Scaffold Type, 2017–2027
        13.6.1. Cobalt Chromium
        13.6.2. Platinum Chromium
        13.6.3. Nitinol
        13.6.4. Biodegradable
        13.6.5. Others
    13.7. North America Drug-eluting Stents Market Value Forecast, by Application, 2017–2027
        13.7.1. Coronary Diseases
        13.7.2. Peripheral Vascular Diseases
    13.8. North America Drug-eluting Stents Market Value Forecast, by End-user, 2017–2027
        13.8.1. Hospitals
        13.8.2. Ambulatory Surgical Centers
    13.9. North America Drug-eluting Stents Market Value Forecast, by Country, 2017–2027
        13.9.1. 1. U.S.
        13.9.2. Canada
    13.10. North America Drug-eluting Stents Market Attractiveness Analysis 
        13.10.1. By Product 
        13.10.2. By Drug 
        13.10.3. By Generation 
        13.10.4. By Scaffold Type 
        13.10.5. By Application 
        13.10.6. By End-user 
        13.10.7. By Country
14. Europe Drug-eluting Stents Market Analysis and Forecast
    14.1. Introduction
    14.2. Key Findings
    14.3. Europe Drug-eluting Stents Market Value Forecast, by Product, 2017–2027
        14.3.1. Polymer-based
            14.3.1.1. Biodegradable Polymers
            14.3.1.2. Durable Polymers
        14.3.2. Polymer-free
    14.4. Europe Drug-eluting Stents Market Value Forecast, by Drug, 2017–2027
        14.4.1. Sirolimus
        14.4.2. Paclitaxel
        14.4.3. Zotarolimus
        14.4.4. Everolimus 
        14.4.5. Biolimus
        14.4.6. Others
    14.5. Europe Drug-eluting Stents Market Value Forecast, by Generation, 2017–2027
        14.5.1. 1st Generation
        14.5.2. 2nd Generation
        14.5.3. 3rd Generation
        14.5.4. 4th Generation
    14.6. Europe Drug-eluting Stents Market Value Forecast, by Scaffold Type, 2017–2027
        14.6.1. Cobalt Chromium
        14.6.2. Platinum Chromium
        14.6.3. Nitinol
        14.6.4. Biodegradable
        14.6.5. Others
    14.7. Europe Drug-eluting Stents Market Value Forecast, by Application, 2017–2027
        14.7.1. Coronary Diseases
        14.7.2. Peripheral Vascular Diseases
    14.8. Europe Drug-eluting Stents Market Value Forecast, by End-user, 2017–2027
        14.8.1. Hospitals
        14.8.2. Ambulatory Surgical Centers
    14.9. Europe Drug-eluting Stents Market Value Forecast, by Country/Sub-region, 2017–2027
        14.9.1. Germany
        14.9.2. U.K.
        14.9.3. France
        14.9.4. Spain
        14.9.5. Italy
        14.9.6. Rest of Europe
    14.10. Europe Drug-eluting Stents Market Attractiveness Analysis 
        14.10.1. By Product 
        14.10.2. By Drug 
        14.10.3. By Generation 
        14.10.4. By Scaffold Type 
        14.10.5. By Application 
        14.10.6. By End-user 
        14.10.7. By Country/Sub-region
15. Asia Pacific Drug-eluting Stents Market Analysis and Forecast
    15.1. Introduction
    15.2. Key Findings
    15.3. Asia Pacific Drug-eluting Stents Market Value Forecast, by Product, 2017–2027
        15.3.1. Polymer-based
            15.3.1.1. Biodegradable Polymers
            15.3.1.2. Durable Polymers
        15.3.2. Polymer-free
    15.4. Asia Pacific Drug-eluting Stents Market Value Forecast, by Drug, 2017–2027
        15.4.1. Sirolimus
        15.4.2. Paclitaxel
        15.4.3. Zotarolimus
        15.4.4. Everolimus 
        15.4.5. Biolimus
        15.4.6. Others
    15.5. Asia Pacific Drug-eluting Stents Market Value Forecast, by Generation, 2017–2027
        15.5.1. 1st Generation
        15.5.2. 2nd Generation
        15.5.3. 3rd Generation
        15.5.4. 4th Generation
    15.6. Asia Pacific Drug-eluting Stents Market Value Forecast, by Scaffold Type, 2017–2027
        15.6.1. Cobalt Chromium
        15.6.2. Platinum Chromium
        15.6.3. Nitinol
        15.6.4. Biodegradable
        15.6.5. Others
    15.7. Asia Pacific Drug-eluting Stents Market Value Forecast, by Application, 2017–2027
        15.7.1. Coronary Diseases
        15.7.2. Peripheral Vascular Diseases
    15.8. Asia Pacific Drug-eluting Stents Market Value Forecast, by End-user, 2017–2027
        15.8.1. Hospitals
        15.8.2. Ambulatory Surgical Centers
    15.9. Asia Pacific Drug-eluting Stents Market Value Forecast, by Country/Sub-region, 2017–2027
        15.9.1. China
        15.9.2. Japan
        15.9.3. India
        15.9.4. Australia & New Zealand
        15.9.5. Rest of Asia Pacific
    15.10. Asia Pacific Drug-eluting Stents Market Attractiveness Analysis 
        15.10.1. By Product 
        15.10.2. By Drug 
        15.10.3. 15.9By Generation 
        15.10.4. By Scaffold Type 
        15.10.5. By Application 
        15.10.6. By End-user 
        15.10.7. By Country/Sub-region
16. Latin America Drug-eluting Stents Market Analysis and Forecast
    16.1. Introduction
    16.2. Key Findings
    16.3. Latin America Drug-eluting Stents Market Value Forecast, by Product, 2017–2027
        16.3.1. Polymer-based
            16.3.1.1. Biodegradable Polymers
            16.3.1.2. Durable Polymers
        16.3.2. Polymer-free
    16.4. Latin America Drug-eluting Stents Market Value Forecast, by Drug, 2017–2027
        16.4.1. Sirolimus
        16.4.2. Paclitaxel
        16.4.3. Zotarolimus
        16.4.4. Everolimus 
        16.4.5. Biolimus
        16.4.6. Others
    16.5. Latin America Drug-eluting Stents Market Value Forecast, by Generation, 2017–2027
        16.5.1. 1st Generation
        16.5.2. 2nd Generation
        16.5.3. 3rd Generation
        16.5.4. 4th Generation
    16.6. Latin America Drug-eluting Stents Market Value Forecast, by Scaffold Type, 2017–2027
        16.6.1. Cobalt Chromium
        16.6.2. Platinum Chromium
        16.6.3. Nitinol
        16.6.4. Biodegradable
        16.6.5. Others
    16.7. Latin America Drug-eluting Stents Market Value Forecast, by Application, 2017–2027
        16.7.1. Coronary Diseases
        16.7.2. Peripheral Vascular Diseases
    16.8. Latin America Drug-eluting Stents Market Value Forecast, by End-user, 2017–2027
        16.8.1. Hospitals
        16.8.2. Ambulatory Surgical Centers
    16.9. Latin America Drug-eluting Stents Market Value Forecast, by Country/Sub-region, 2017–2027
        16.9.1. Brazil
        16.9.2. Mexico
        16.9.3. Rest of Latin America
    16.10. Latin America Drug-eluting Stents Market Attractiveness Analysis 
        16.10.1. By Product 
        16.10.2. By Drug 
        16.10.3. By Generation 
        16.10.4. By Scaffold Type 
        16.10.5. By Application 
        16.10.6. By End-user 
        16.10.7. By Country/Sub-region
17. Middle East & Africa Drug-eluting Stents Market Analysis and Forecast
    17.1. Introduction
    17.2. Key Findings
    17.3. Middle East & Africa Drug-eluting Stents Market Value Forecast, by Product, 2017–2027
        17.3.1. Polymer-based
            17.3.1.1. Biodegradable Polymers
            17.3.1.2. Durable Polymers
        17.3.2. Polymer-free
    17.4. Middle East & Africa Drug-eluting Stents Market Value Forecast, by Drug, 2017–2027
        17.4.1. Sirolimus
        17.4.2. Paclitaxel
        17.4.3. Zotarolimus
        17.4.4. Everolimus 
        17.4.5. Biolimus
        17.4.6. Others
    17.5. Middle East & Africa Drug-eluting Stents Market Value Forecast, by Generation, 2017–2027
        17.5.1. 1st Generation
        17.5.2. 2nd Generation
        17.5.3. 3rd Generation
        17.5.4. 4th Generation
    17.6. Middle East & Africa Drug-eluting Stents Market Value Forecast, by Scaffold Type, 2017–2027
        17.6.1. Cobalt Chromium
        17.6.2. Platinum Chromium
        17.6.3. Nitinol
        17.6.4. Biodegradable
        17.6.5. Others
    17.7. Middle East & Africa Drug-eluting Stents Market Value Forecast, by Application, 2017–2027
        17.7.1. Coronary Diseases
        17.7.2. Peripheral Vascular Diseases
    17.8. Market Value Forecast, by End-user, 2017–2027
        17.8.1. Hospitals
        17.8.2. Ambulatory Surgical Centers
    17.9. Market Value Forecast, by Country/Sub-region, 2017–2027
        17.9.1. GCC Countries
        17.9.2. South Africa
        17.9.3. Rest of Middle East & Africa
    17.10. Middle East & Africa Drug-eluting Stents Market Attractiveness Analysis 
        17.10.1. By Product 
        17.10.2. By Drug 
        17.10.3. By Generation 
        17.10.4. By Scaffold Type 
        17.10.5. By Application 
        17.10.6. By End-user 
        17.10.7. By Country/Sub-region
18. Competition Landscape
    18.1. Market Player – Competition Matrix (By Tier and Size of companies)
    18.2. Market Share Analysis by Company (2018)
    18.3. Company Profiles
        18.3.1. Boston Scientific Corporation
            18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            18.3.1.2. Financial Overview
            18.3.1.3. Product Portfolio
            18.3.1.4. SWOT Analysis
            18.3.1.5. Strategic Overview
        18.3.2. Medtronic
            18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            18.3.2.2. Financial Overview
            18.3.2.3. Product Portfolio
            18.3.2.4. SWOT Analysis
            18.3.2.5. Strategic Overview
        18.3.3. Abbott
            18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            18.3.3.2. Financial Overview
            18.3.3.3. Product Portfolio
            18.3.3.4. SWOT Analysis
            18.3.3.5. Strategic Overview
        18.3.4. Biosensors International Group, Ltd (Bluesail Medical Co., Ltd.)
            18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            18.3.4.2. Product Portfolio
            18.3.4.3. SWOT Analysis
            18.3.4.4. Strategic Overview
        18.3.5. Biotronik
            18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            18.3.5.2. Product Portfolio
            18.3.5.3. SWOT Analysis
            18.3.5.4. Strategic Overview
        18.3.6. MicroPort Scientific Corporation
            18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            18.3.6.2. Financial Overview
            18.3.6.3. Product Portfolio
            18.3.6.4. SWOT Analysis
            18.3.6.5. Strategic Overview
        18.3.7. Terumo Corporation
            18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            18.3.7.2. Financial Overview
            18.3.7.3. Product Portfolio
            18.3.7.4. SWOT Analysis
            18.3.7.5. Strategic Overview
        18.3.8. Cook
            18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            18.3.8.2. Product Portfolio
            18.3.8.3. SWOT Analysis
            18.3.8.4. Strategic Overview
        18.3.9. STENTYS SA
            18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            18.3.9.2. Financial Overview
            18.3.9.3. Product Portfolio
            18.3.9.4. SWOT Analysis
            18.3.9.5. Strategic Overview
        18.3.10. Medinol Ltd
            18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            18.3.10.2. Product Portfolio
            18.3.10.3. SWOT Analysis
            18.3.10.4. Strategic Overview

List of Tables

Table 01 Regulatory Approvals in Drug-eluting Stents Market (1/2)
Table 02 Regulatory Approvals in Drug-eluting Stents Market (2/2)
Table 03 Product Launch in Drug-eluting Stents Market
Table 04 Global Drug-eluting Stents Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 05 Global Drug-eluting Stents Market Value (US$ Mn) Forecast, by Polymer-based Type, 2017–2027
Table 06 Global Drug-eluting Stents Market Value (US$ Mn) Forecast, by Drug, 2017–2027
Table 07 Global Drug-eluting Stents Market Value (US$ Mn) Forecast, by Generation, 2017–2027
Table 08 Global Drug-eluting Stents Market Value (US$ Mn) Forecast, by Scaffold, 2017–2027
Table 09 Global Drug-eluting Stents  Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 10 Global Drug-eluting Stents  Market Value (US$ Mn) Forecast, by End User, 2017–2027
Table 11 Global Drug-eluting Stents Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 12 North America Drug-eluting Stents Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 13 North America Drug-eluting Stents Market Value (US$ Mn) Forecast, by Polymer-based Type, 2017–2027
Table 14 North America Drug-eluting Stents Market Value (US$ Mn) Forecast, by Drug, 2017–2027
Table 15 North America Drug-eluting Stents Market Value (US$ Mn) Forecast, by Generation, 2017–2027
Table 16 North America Drug-eluting Stents Market Value (US$ Mn) Forecast, by Scaffold, 2017–2027
Table 17 North America Drug-eluting Stents Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 18 North America Drug-eluting Stents Market Value (US$ Mn) Forecast, by End User, 2017–2027
Table 19 North America Drug-eluting Stents Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 20 Europe Drug-eluting Stents Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 21 Europe Drug-eluting Stents Market Value (US$ Mn) Forecast, by Polymer-based Type, 2017–2027
Table 22 Europe Drug-eluting Stents Market Value (US$ Mn) Forecast, by Drug, 2017–2027
Table 23 Europe Drug-eluting Stents Market Value (US$ Mn) Forecast, by Generation, 2017–2027
Table 24 Europe Drug-eluting Stents Market Value (US$ Mn) Forecast, by Scaffold, 2017–2027
Table 25 Europe Drug-eluting Stents Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 26 Europe Drug-eluting Stents Market Value (US$ Mn) Forecast, by End User, 2017–2027
Table 27 Europe Drug-eluting Stents Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 28 Asia Pacific Drug-eluting Stents Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 29 Asia Pacific Drug-eluting Stents Market Value (US$ Mn) Forecast, by Polymer-based Type, 2017–2027
Table 30 Asia Pacific Drug-eluting Stents Market Value (US$ Mn) Forecast, by Drug, 2017–2027
Table 31 Asia Pacific Drug-eluting Stents Market Value (US$ Mn) Forecast, by Generation, 2017–2027
Table 32 Asia Pacific Drug-eluting Stents Market Value (US$ Mn) Forecast, by Scaffold, 2017–2027
Table 33 Asia Pacific Drug-eluting Stents Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 34 Asia Pacific Drug-eluting Stents Market Value (US$ Mn) Forecast, by End User, 2017–2027
Table 35 Asia Pacific Drug-eluting Stents Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 36 Latin America Drug-eluting Stents Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 37 Latin America Drug-eluting Stents Market Value (US$ Mn) Forecast, by Polymer-based Type, 2017–2027
Table 38 Latin America Drug-eluting Stents Market Value (US$ Mn) Forecast, by Drug, 2017–2027
Table 39 Latin America Drug-eluting Stents Market Value (US$ Mn) Forecast, by Generation, 2017–2027
Table 40 Latin America Drug-eluting Stents Market Value (US$ Mn) Forecast, by Scaffold, 2017–2027
Table 41 Latin America Drug-eluting Stents Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 42 Latin America Drug-eluting Stents Market Value (US$ Mn) Forecast, by End User, 2017–2027
Table 43 Latin America Drug-eluting Stents Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 44 Middle East & Africa Drug-eluting Stents Market Value (US$ Mn) Forecast, by Product, 2017–2027
Table 45 Middle East & Africa Drug-eluting Stents Market Value (US$ Mn) Forecast, by Polymer-based Type, 2017–2027
Table 46 Middle East & Africa Drug-eluting Stents Market Value (US$ Mn) Forecast, by Drug, 2017–2027
Table 47 Middle East & Africa Drug-eluting Stents Market Value (US$ Mn) Forecast, by Generation, 2017–2027
Table 48 Middle East & Africa Drug-eluting Stents Market Value (US$ Mn) Forecast, by Scaffold, 2017–2027
Table 49 Middle East & Africa Drug-eluting Stents Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 50 Middle East & Africa Drug-eluting Stents Market Value (US$ Mn) Forecast, by End User, 2017–2027
Table 51 Middle East & Africa Drug-eluting Stents Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

List of Figures

Figure 01 Strategic Approaches by Market Players (Acquisitions, Partnerships, and Distribution Agreements, etc.) in Drug-eluting Stents Market (1/2)
Figure 02 Strategic Approaches by Market Players (Acquisitions, Partnerships, and Distribution Agreements, etc.) in Drug-eluting Stents Market (2/2)
Figure 03 Global Drug-eluting Stents Market Value Share Analysis, by Product, 2018 and 2027
Figure 04 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Polymer-based, 2017–2027
Figure 05 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Polymer-free, 2017–2027
Figure 06 Global Drug-eluting Stents Market Attractiveness, by Product, 2019–2027
Figure 07 Global Drug-eluting Stents Market Value Share Analysis, by Drug, 2018 and 2027
Figure 08 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Sirolimus, 2017–2027
Figure 09 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Everolimus, 2017–2027
Figure 10 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Paclitaxel, 2017–2027
Figure 11 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Zotarolimus, 2017–2027
Figure 12 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Biolimus, 2017–2027
Figure 13 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017–2027
Figure 14 Global Drug-eluting Stents Market Attractiveness, by Drug, 2019–2027
Figure 15 Global Drug-eluting Stents Market Value Share Analysis, by Generation, 2018 and 2027
Figure 16 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by 1st Generation, 2017–2027
Figure 17 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by 2nd Generation, 2017–2027
Figure 18 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by 3rd Generation, 2017–2027
Figure 19 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by 4th Generation, 2017–2027
Figure 20 Global Drug-eluting Stents Market Attractiveness, by Generation, 2019–2027
Figure 21 Global Drug-eluting Stents Market Value Share Analysis, by Scaffold, 2018 and 2027
Figure 22 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Cobalt Chromium, 2017–2027
Figure 23 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Platinum Chromium, 2017–2027
Figure 24 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Nitinol, 2017–2027
Figure 25 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Biodegradable, 2017–2027
Figure 26 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Biolimus, 2017–2027
Figure 27 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017–2027
Figure 28 Global Drug-eluting Stents Market Attractiveness, by Scaffold, 2019–2027
Figure 29 Global Drug-eluting Stents Market Value Share Analysis, by Application, 2018 and 2027
Figure 30 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Coronary Diseases, 2017–2027
Figure 31 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Peripheral Vascular Diseases, 2017–2027
Figure 32 Global Drug-eluting Stents Market Attractiveness, by Application, 2019–2027
Figure 33 Global Drug-eluting Stents Market Value Share Analysis, by End User, 2018 and 2027
Figure 34 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospitals, 2017–2027
Figure 35 Global Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Ambulatory Surgical Centers, 2017–2027
Figure 36 Global Drug-eluting Stents Market Attractiveness, by End User, 2019–2027
Figure 37 Global Drug-eluting Stents Market Value Share (%), by Region, 2018 and 2027
Figure 38 Global Drug-eluting Stents Market Attractiveness, by Region, 2019–2027
Figure 39 North America Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 40 North America Drug-eluting Stents Market Value Share Analysis, by Product, 2018 and 2027
Figure 41 North America Drug-eluting Stents Market Attractiveness Analysis, by Product, 2019–2027
Figure 42 North America Drug-eluting Stents Market Value Share Analysis, by Drug, 2018 and 2027
Figure 43 North America Drug-eluting Stents Market Attractiveness Analysis, by Drug, 2019–2027
Figure 44 North America Drug-eluting Stents Market Value Share Analysis, by Generation, 2018 and 2027
Figure 45 North America Drug-eluting Stents Market Attractiveness Analysis, by Generation, 2019–2027
Figure 46 North America Drug-eluting Stents Market Value Share Analysis, by Scaffold, 2018 and 2027
Figure 47 North America Drug-eluting Stents Market Attractiveness Analysis, by Scaffold, 2019–2027
Figure 48 North America Drug-eluting Stents Market Value Share Analysis, by Application, 2018 and 2027
Figure 49 North America Drug-eluting Stents Market Attractiveness Analysis, by Application, 2019–2027
Figure 50 North America Drug-eluting Stents Market Value Share Analysis, by End User, 2018 and 2027
Figure 51 North America Drug-eluting Stents Market Attractiveness Analysis, by End User, 2019–2027
Figure 52 North America Drug-eluting Stents Market Attractiveness Analysis, by Country, 2019–2027
Figure 53 North America Drug-eluting Stents Market Value Share Analysis, by Country, 2018 and 2027
Figure 54 Europe Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 55 Europe Drug-eluting Stents Market Value Share Analysis, by Product, 2018 and 2027
Figure 56 Europe Drug-eluting Stents Market Attractiveness Analysis, by Product, 2019–2027
Figure 57 Europe Drug-eluting Stents Market Value Share Analysis, by Drug, 2018 and 2027
Figure 58 Europe Drug-eluting Stents Market Attractiveness Analysis, by Drug, 2019–2027
Figure 59 Europe Drug-eluting Stents Market Value Share Analysis, by Generation, 2018 and 2027
Figure 60 Europe Drug-eluting Stents Market Attractiveness Analysis, by Generation, 2019–2027
Figure 61 Europe Drug-eluting Stents Market Value Share Analysis, by Scaffold, 2018 and 2027
Figure 62 Europe Drug-eluting Stents Market Attractiveness Analysis, by Scaffold, 2019–2027
Figure 63 Europe Drug-eluting Stents Market Value Share Analysis, by Application, 2018 and 2027
Figure 64 Europe Drug-eluting Stents Market Attractiveness Analysis, by Application, 2019–2027
Figure 65 Europe Drug-eluting Stents Market Value Share Analysis, by End User, 2018 and 2027
Figure 66 Europe Drug-eluting Stents Market Attractiveness Analysis, by End User, 2019–2027
Figure 67 Europe Drug-eluting Stents Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 68 Europe Drug-eluting Stents Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 69 Asia Pacific Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 70 Asia Pacific Drug-eluting Stents Market Value Share Analysis, by Product, 2018 and 2027
Figure 71 Asia Pacific Drug-eluting Stents Market Attractiveness Analysis, by Product, 2019–2027
Figure 72 Asia Pacific Drug-eluting Stents Market Value Share Analysis, by Drug, 2018 and 2027
Figure 73 Asia Pacific Drug-eluting Stents Market Attractiveness Analysis, by Drug, 2019–2027
Figure 74 Asia Pacific Drug-eluting Stents Market Value Share Analysis, by Generation, 2018 and 2027
Figure 75 Asia Pacific Drug-eluting Stents Market Attractiveness Analysis, by Generation, 2019–2027
Figure 76 Asia Pacific Drug-eluting Stents Market Value Share Analysis, by Scaffold, 2018 and 2027
Figure 77 Asia Pacific Drug-eluting Stents Market Attractiveness Analysis, by Scaffold, 2019–2027
Figure 78 Asia Pacific Drug-eluting Stents Market Value Share Analysis, by Application, 2018 and 2027
Figure 79 Asia Pacific Drug-eluting Stents Market Attractiveness Analysis, by Application, 2019–2027
Figure 80 Asia Pacific Drug-eluting Stents Market Value Share Analysis, by End User, 2018 and 2027
Figure 81 Asia Pacific Drug-eluting Stents Market Attractiveness Analysis, by End User, 2019–2027
Figure 82 Asia Pacific Drug-eluting Stents Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 83 Asia Pacific Drug-eluting Stents Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 84 Latin America Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 85 Latin America Drug-eluting Stents Market Value Share Analysis, by Product, 2018 and 2027
Figure 86 Latin America Drug-eluting Stents Market Attractiveness Analysis, by Product, 2019–2027
Figure 87 Latin America Drug-eluting Stents Market Value Share Analysis, by Drug, 2018 and 2027
Figure 88 Latin America Drug-eluting Stents Market Attractiveness Analysis, by Drug, 2019–2027
Figure 89 Latin America Drug-eluting Stents Market Value Share Analysis, by Generation, 2018 and 2027
Figure 90 Latin America Drug-eluting Stents Market Attractiveness Analysis, by Generation, 2019–2027
Figure 91 Latin America Drug-eluting Stents Market Value Share Analysis, by Scaffold, 2018 and 2027
Figure 92 Latin America Drug-eluting Stents Market Attractiveness Analysis, by Scaffold, 2019–2027
Figure 93 Latin America Drug-eluting Stents Market Value Share Analysis, by Application, 2018 and 2027
Figure 94 Latin America Drug-eluting Stents Market Attractiveness Analysis, by Application, 2019–2027
Figure 95 Latin America Drug-eluting Stents Market Value Share Analysis, by End User, 2018 and 2027
Figure 96 Latin America Drug-eluting Stents Market Attractiveness Analysis, by End User, 2019–2027
Figure 97 Latin America Drug-eluting Stents Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 98 Latin America Drug-eluting Stents Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 99 Middle East & Africa Drug-eluting Stents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 100 Middle East & Africa Drug-eluting Stents Market Value Share Analysis, by Product, 2018 and 2027
Figure 101 Middle East & Africa Drug-eluting Stents Market Attractiveness Analysis, by Product, 2019–2027
Figure 102 Middle East & Africa Drug-eluting Stents Market Value Share Analysis, by Drug, 2018 and 2027
Figure 103 Middle East & Africa Drug-eluting Stents Market Attractiveness Analysis, by Drug, 2019–2027
Figure 104 Middle East & Africa Drug-eluting Stents Market Value Share Analysis, by Generation, 2018 and 2027
Figure 105 Middle East & Africa Drug-eluting Stents Market Attractiveness Analysis, by Generation, 2019–2027
Figure 106 Middle East & Africa Drug-eluting Stents Market Value Share Analysis, by Scaffold, 2018 and 2027
Figure 107 Middle East & Africa Drug-eluting Stents Market Attractiveness Analysis, by Scaffold, 2019–2027
Figure 108 Figure 43: Middle East & Africa Drug-eluting Stents Market Value Share Analysis, by Application, 2018 and 2027
Figure 109 Middle East & Africa Drug-eluting Stents Market Attractiveness Analysis, by Application, 2019–2027
Figure 110 Middle East & Africa Drug-eluting Stents Market Value Share Analysis, by End User, 2018 and 2027
Figure 111 Middle East & Africa Drug-eluting Stents Market Attractiveness Analysis, by End User, 2019–2027
Figure 112 Middle East & Africa Drug-eluting Stents Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 113 Middle East & Africa Drug-eluting Stents Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Drug Eluting Stents Market